Quoin Pharmaceuticals

Today we shared our Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results. "2025 was a defining year for @QuoinPharma we transitioned from clinical stage to a company actively preparing for commercial readiness." — Michael Myers, CEO Key highlights include: · Closed a private placement financing of up to $104.5 million, strengthening our balance sheet and funding operations into 2027 · Orphan Drug Designations in the U.S. and Europe · Fast Track Designation in the U.S. for QRX003 in Netherton Syndrome · Continued progress toward expedited regulatory pathways in Japan and Saudi Arabia · Expansion of our pediatric Netherton Syndrome study to 7 actively treated children, the largest cohort of this age group ever studied · Continued advancement of our Peeling Skin Syndrome and topical rapamycin programs, including expansion of the Peeling Skin Syndrome study to 6 subjects · NETHERTON NOW reaching nearly 2 million video views and 24 million global impressions As we move into 2026, we remain focused on advancing QRX003 and expanding our pipeline on behalf of patients and families living with rare and orphan diseases. We look forward to sharing further progress throughout the year. #QNRX investors.quoinpharma.com/news-releases/…

An important regulatory milestone for @QuoinPharma . Following a constructive Type C meeting with the U.S. Food and Drug Administration, we are advancing our Phase 3 plans for QRX003 in Netherton Syndrome, a rare and severe genetic skin disease with no approved treatments. The FDA indicated that a single Phase 3 study may be sufficient to support U.S. marketing approval and supported consideration of clinical trial designs that may better align with this patient population. This feedback provides increased clarity on the regulatory path forward and strengthens our confidence as we advance our pivotal program. Quoin remains on track to initiate Phase 3 and complete patient recruitment in 2026, with the potential to file an NDA in 2027. Today’s update marks an important step forward in our mission to develop a potential treatment for patients and families living with Netherton Syndrome who have waited so long. $QNRX investors.quoinpharma.com/news-releases/…

.@QuoinPharma (NASDAQ: $QNRX) will report its corporate update and full-year 2025 financial results on March 26, 2026 before market open. Read more : investors.quoinpharma.com/news-releases/…

Regulatory milestone for Quoin Pharmaceuticals. The FDA has granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disease with no approved treatments. QRX003 is currently being evaluated in two late-stage clinical trials. The designation builds on prior Orphan Drug and Rare Pediatric Disease Designations. $QNRX investors.quoinpharma.com/news-releases/…

Since launching NETHERTON NOW at the start of Rare Disease Month 2025, the response has been extraordinary — nearly 2 million video views and more than 24 million impressions globally. As Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, said: "What stands out most is the courage of the patients and families who chose to share their experiences. Individuals who had previously lived in silence now have a platform to share their stories, connect with one another, and help bring greater understanding of Netherton Syndrome to the broader medical and advocacy communities." We are deeply grateful to every patient, caregiver, and clinician who made NETHERTON NOW what it has become. $QNRX #nethertonnow

As Rare Disease Month kicks off, Quoin Pharmaceuticals $QNRX highlights progress for children and families affected by rare diseases, following the FDA’s extension of the Rare Pediatric Disease Priority Review Voucher program through 2029.

Quoin Pharmaceuticals $QNRX submitted an application to Japan’s MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome. MHLW confirmed eligibility for both Orphan Drug Designation and Fast Track review, strengthening QRX003’s global regulatory positioning across the U.S., Europe, and Japan.investors.quoinpharma.com/news-releases/…

.@QuoinPharma announced it has filed for Breakthrough Medicine Designation in Saudi Arabia for QRX003 in Netherton Syndrome. This is the first time globally an accelerated regulatory pathway has been pursued for a treatment specifically targeting Netherton Syndrome. If granted, QRX003 could be approved for sale and reimbursement as early as 2H 2026. $QNRX investors.quoinpharma.com/news-releases/…

Honored to see QRX003 featured in Dermatology Times’ Drugs to Watch in 2026. For the Netherton syndrome community, this reflects growing focus on a rare condition with no approved treatments. $QNRX Read more: dermatologytimes.com/view/drugs-to-…

MLM and VM have no FDA-approved treatments. Quoin has reached 4% and 5% rapamycin target loadings across two delivery technologies, moving toward clinical batches and 2026 studies. We continue working to bring hope where there is currently none. $QNRX

A meaningful step forward for children and families affected by rare diseases. We are encouraged by the House passage of the Mikaela Naylon Give Kids a Chance Act, which would reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) program. This program plays an essential role in supporting innovation for serious pediatric conditions that currently lack approved therapies. Reauthorization is especially important for diseases where patients and families have few or no treatment options, including Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations and Venous Malformations. These communities urgently need continued progress. We extend our gratitude to the advocates, policymakers, and rare disease champions who advanced this legislation, and we honor the legacy of Mikaela Naylon, whose courage continues to inspire the entire rare disease community. The legislation now moves to the Senate, where continued support is essential. Families living with rare pediatric diseases cannot afford delays. @QuoinPharma remains deeply committed to advancing meaningful treatments and supporting families across the rare disease community. $QNRX pharmaceutical-technology.com/news/house-pas… --

As Thanksgiving approaches, we’re especially grateful for our NETHERTON NOW ambassadors, their families, and the outpouring of support from so many across the community. Thank you for sharing your journeys with strength, honesty, and grace.From all of us at Quoin, we wish you and your families a safe, restful, and meaningful holiday. $QNRX #NethertonNow

We’re excited to announce that $QNRX has achieved 4% and 5% rapamycin loadings in our proprietary topical lotion and dermal patch technologies — a key step toward upcoming trials in rare lymphatic and venous malformations. bit.ly/4o0fx0Y